Skip to content
MARKETS / NASDAQ / PPBT
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Purple Biotech Ltd. PPBT

11 fiscal years on record · USD · FY2025 reported · SEC filings only
$-26.4M
$-5.7M
In brief

What this company does

We are focused on advancing our lead program, CAPTN-3 - a platform of masked tri-specific antibodies that simultaneously target tumors while engaging both T cells and NK cells. CAPTN-3: A platform of masked tri-specific antibodies that simultaneously target tumor-associated antigens while engaging both T cells and NK cells. CM24, is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression. NT219: A dual-inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two major survival signal transduction pathways driving the development of cancer drug resistance.

Written from the business description in Purple Biotech Ltd.'s annual report to the U.S. Securities and Exchange Commission, filed 19 March 2026. Every sentence was checked against that document before publication.

Growth
Revenue, FY2025 · full 11-year series below
Revenue $M Net income $M
FY2020 · Revenue 1.0 · Net income 28.0
10M20M201520172019202120232025
Compound annual growth
+115.4%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
Operating margin Net margin
FY2020 · Operating -1261.2% · Net 2807.4%
5000%10000%-5000%-10000%201520172019202120232025
ROE
FY2025 · ROE -124.0%
50%100%-50%-100%201520172019202120232025

Each USD of equity lost 124 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -5.7
-8M-16M201520172019202120232025

Total assetsUSD 17.6M
EquityUSD 9.7M
CashUSD 8.7M
Current ratio1.27×

Equity funds 55% of total assets.

The 11-year record
11 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021202020192018201720162015
Revenue $B·····0.00.00.00.0··
Operating income $B··−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B···········
Income tax $B······0.0····
Net income $B−0.0−0.0−0.0−0.00.00.00.00.00.00.00.0
Free cash flow $B−0.0·−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $0.034.99−17.96−23.9717568036.00······
Dividend / sh $···········
Payout %···········
ROE %−124.0−21.6−49.0−38.825.562.455.958.0117.190.6·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 1 failures in 36 reconciliationsAUDITED

Reconciled in 10 of 19 fiscal years. 40 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente1 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code L3
Fiscal year endsDecember 31
Data on record since2015

Share this section

Download image